Sonoran’s lead product, SBG002, is being developed for prevention of SSI. SBG002 contains the antibiotics tobramycin and vancomycin, which together have a long history of clinical use and are effective against over 95% of the bacteria found in SSIs. SBG002 is intended to be injected in a surgical site after surgery is completed.
SBG002 provides extreme antibiotic levels throughout the surgical site for multiple days, 100-1,000 times the levels that are safely achievable by conventional intravenous or oral dosing. We believe that the quality of preclinical data on SBG002 is unmatched by any technology, including those in clinical trials for SSI prevention and treatment.